ADHD

There are several clinical trials testing psychedelics as a treatment option for psychiatric disorders.

There are a number of ongoing clinical trials testing psychedelics as a treatment for psychiatric disorders.

Schizophrenia PRS was linked to increased disorganized symptom dimension scores.

The COVID-19 pandemic may have exposed more disparities based on race or ethnicity in ADHD care.

CBGT and MBSR were both associated with a significant decrease in negative emotion.

Researchers found the strongest associations between ADHD and nervous system disorders and respiratory diseases.

Methylphenidate hydrochloride (Adhansia XR) was originally approved in 2019 for ADHD patients at least 6 years old.

Viloxazine was approved in April by the FDA for pediatric ADHD patients between 6-17 years old.

Externalizing ADHD symptoms was linked to suicidality.

Greater symptoms of depression, anxiety, and ADHD were associated with less sleep.

Andrew J. Cutler, MD discusses new research into the efficacy and safety of a D-ATS treatment in children with ADHD.

Impaired reward processing could influence the presentation of sleep disturbances for patients with ADHD.

Adults often do not suffer from the symptoms of hyperactivity in ADHD.

New data show ADHD-specific text message intervention beneficial to patients who may have low rate of stimulant treatment adherence.

The transition from pediatric care to adult care can be confusing for ADHD patients, often leading to a discontinuation of health care services altogether.

The rates of both diseases have been increasingly linked in recent years.

Investigators conclude data show diminishing returns in treating mild cases of ADHD, but more research is needed to bridge long-term positives and negatives.

The main predictors of SCWT performance was maternal education and housing conditions.

The approval comes after Supernus resubmitted an application to address issues outlined in a FDA CRL.

The study represents the first to examine a PPD connection to allopregnanolone.

The analysis was less statistically powered when comparing sibling discordant.

Optimizing care and managing challenges for patients with ADHD during the COVID-19 pandemic and advice for clinicians educating patients and families on disease management.

Rakesh Jain, MD, MPH, shares his thoughts on whether drug holidays are appropriate for children taking medication for ADHD.

A discussion on the recent development of investigational serotonin norepinephrine modulating agent (SNMA), SPN-812, for the treatment of ADHD in adults.

Rakesh Jain, MD, MPH, considers the evidence-based recommended hierarchy in the choice of medications for the treatment of pediatric and adult ADHD.